Skip to main content

Table 2 Daily cost per regimen

From: Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands

Regimen

Daily cost (€)

Stage 1 – TPV/r + background antiretrovirals

71.70

Stage 1 – CPI/r + background antiretrovirals

55.74

Stage 2 – New HAART regimen

44.04

Stage 3 – Salvage HAART regimen

51.22

  1. Daily cost (Euro price level 2006) per regimen in the Netherlands
  2. TPV/r: tipranavir with ritonavir
  3. CPI/r: comparator protease inhibitor with ritonavir
  4. HAART: highly active antiretroviral therapy
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us